MedPath

Cardiac Resynchronization Therapy Efficacy Enhancements

Not Applicable
Completed
Conditions
Atrial Fibrillation
Interventions
Device: Conducted AF Response (CAFR)
Device: Conducted AF Response Plus (CAFRPlus)
Registration Number
NCT02222818
Lead Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Brief Summary

The purpose of this study is to demonstrate that the amount of effective CRT (Cardiac Resynchronization Therapy) pacing during AF (atrial fibrillation) when CAFRPlus (Conducted AF Response Plus) is applied is not inferior to the amount of effective CRT pacing during AF when CAFR (Conducted AF Response) is applied.

Detailed Description

The CRTee study is an IDE, prospective, multi-center, randomized, controlled, crossover clinical study, conducted worldwide and designed to demonstrate that the amount of effective CRT pacing during AF (atrial fibrillation) when CAFRPlus (Conducted AF Response Plus) is applied is not inferior to the amount of effective CRT pacing during AF when CAFR (Conducted AF Response) is applied.

The study will be conducted at up to 30 centers located in the United States, Europe and Middle East and Africa (MEA).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
71
Inclusion Criteria
  • Subject is willing to sign and date the study patient Informed Consent form.
  • Subject is at least 18 years of age (or older, if required by local law).
  • Subject is expected to remain available after enrollment to complete follow-up visits in both arms of the study
  • Subject has had a Medtronic Viva or Brava CRT-D device implanted at least 30 days prior to enrollment.
  • Subject has history of AF burden, of at least 6 days of at least 4 hours of AF over any 4 week period within the last 90 days as documented in device diagnostic data OR if subject has no atrial lead (therefore no device diagnostic data) but clinical evidence of high AF burden.
  • Subject has demonstrated history of being able to complete Left Ventricular Capture Management (LVCM) documented in device data.
  • Subject has a documented % V pacing during AF of less than or equal to 97% within 90 days prior to enrollment or within 10 days after enrollment.
Exclusion Criteria
  • Subject has undergone AV node ablation for treatment of AF.
  • Subject has complete or 3rd degree AV block.
  • Subject has had an MI within 30 days.
  • Subject has medical conditions that limit study participation (per physician discretion).
  • Subject is enrolled in one or more concurrent studies that could confound the study results as determined by Medtronic.
  • Subject has a limited life expectancy for non-cardiac causes that would not allow completion of the study.
  • Subject is pregnant (in the US, all women of child-bearing potential must undergo a pregnancy test within seven days prior to CRTee download).
  • Subject meets the exclusion criteria required by local law.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Group A: CAFR firstConducted AF Response (CAFR)Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
Group B: CAFRPlus firstConducted AF Response (CAFR)Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
Group A: CAFR firstConducted AF Response Plus (CAFRPlus)Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
Group B: CAFRPlus firstConducted AF Response Plus (CAFRPlus)Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
Primary Outcome Measures
NameTimeMethod
Percentage of Effective CRT Pacing During AF (Non-inferiority Test)Up to 4 months

The primary objective is to demonstrate that the percent effective CRT pacing during AF when CAFRPlus is applied is not inferior to when CAFR is applied (non-inferiority test).

Secondary Outcome Measures
NameTimeMethod
Percentage of Effective CRT Pacing During AF (Superiority Test)Up to 4 months

The secondary objective is to demonstrate that the percent effective CRT pacing during AF when CAFRPlus is applied is greater than when CAFR is applied (superiority test).

Trial Locations

Locations (19)

Cardiac Arrythmia Services

🇺🇸

Boca Raton, Florida, United States

Iowa Heart Center

🇺🇸

West Des Moines, Iowa, United States

North Carolina Heart and Vascular

🇺🇸

Raleigh, North Carolina, United States

North Memorial Heart and Vascular

🇺🇸

Minneapolis, Minnesota, United States

CentraCare

🇺🇸

St. Cloud, Minnesota, United States

Mount Carmel

🇺🇸

Columbus, Ohio, United States

Berks Cardiology

🇺🇸

Reading, Pennsylvania, United States

Oklahoma Heart

🇺🇸

Oklahoma City, Oklahoma, United States

Kootenai Heart Clinics

🇺🇸

Spokane, Washington, United States

Texas Cardiac Arrhythmia Services

🇺🇸

Austin, Texas, United States

Azienda Ospedaliera Bolognini Seriate - Ospedale Bolognini

🇮🇹

Seriate, Italy

Policlinico Universitario Agostino Gemelli

🇮🇹

Roma, Italy

Azienda Ospedaliera Cardinale Panico

🇮🇹

Tricase, Italy

Mediclinic Panorama

🇿🇦

Cape Town, South Africa

Liverpool Heart and Chest Hospital NHS Foundation Trust

🇬🇧

Liverpool, United Kingdom

he Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital

🇬🇧

Newcastle Upon Tyne, United Kingdom

Magyar Honvédség Honvédkorház

🇭🇺

Budapest, Hungary

Prince Sultan Cardiac Center

🇸🇦

Riyadh, Saudi Arabia

Vychodoslovensky ustav srdcovych a cievnych chorob, a.s.

🇸🇰

Kosice, Slovakia

© Copyright 2025. All Rights Reserved by MedPath